Kervalion

Kervalion, based in France, specializes in providing innovative 3D-printed bone grafts tailored for dental surgeries, enhancing precision and efficiency in dental implant procedures. Kervalion, founded in 2025, operates out of Clapiers, France, focusing on the development of custom 3D-printed bone grafts for dental applications. The company has completed 2 deals to date, including a recent SEED round in March 2026, raising EUR 0. 70 mn, which fully accounts for their total amount raised.

The company’s innovative approach has garnered attention in the dental sector as it continues to refine its offerings. Kervalion specializes in the development of custom 3D-printed bone grafts tailored to individual patients based on their specific scans. These advanced grafts are primarily intended for dental pre-implant surgeries, addressing bone deficiencies that hinder the placement of dental implants. By utilizing advanced 3D printing technology, Kervalion ensures that each graft is designed for optimal shape and volume, significantly simplifying surgical procedures and minimizing the number of necessary interventions.

Kervalion's revenue model is centered around direct transactions with dental practitioners and healthcare facilities requiring their innovative bone grafting solutions. The company offers its flagship 3D-printed bone grafts through a B2B sales structure, establishing partnerships with dental clinics and hospitals performing dental implant surgeries. The pricing structure reflects the advanced technology and personalized service involved in their creation, encompassing a range of costs associated with the bespoke nature of the grafts and the 3D printing process. In March 2026, Kervalion raised EUR 1.

3 million in venture debt funding to advance its patented 3D-printed bone graft technology and enable single-procedure dental implants. The company plans to launch new products that enhance the efficiency of dental procedures while expanding its market presence in regions such as Brazil, Russia, India, and China by late 2027.